Physician profile
Patrick Huott
NPI 1366452781
$5,597.04
in general payments reported to CMS, 2019-2025
33 companies · $2,616 in 2025
The $2,616 reported for 2025 was more than what 77% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.73 · 2024: $2,966 · 2025: $2,616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,555 · Education: $26.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,554.58 |
| Education | $26.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $814.75 | 2024-2025 | Ingrezza |
| Abbvie INC. | $611.70 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $575.00 | 2024-2025 | Austedo Xr, Austedo Xr |
| Ucb, INC. | $501.75 | 2024-2025 | Briviact, Zilbrysq, Nayzilam |
| Novartis Pharmaceuticals Corporation | $337.72 | 2019-2025 | |
| Eisai INC. | $320.66 | 2024-2025 | |
| Biogen, INC. | $276.99 | 2024-2025 | Leqembi, Vumerity, Tysabri |
| Ani Pharmaceuticals, INC. | $273.02 | 2025 | Purified Cortrophin Gel |
| Livanova USA, INC. | $200.29 | 2024-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Lundbeck LLC | $186.07 | 2024-2025 | Vyepti, Rexulti |
| Acadia Pharmaceuticals INC | $182.71 | 2024-2025 | Nuplazid |
| Neurelis, INC. | $155.81 | 2024-2025 | Valtoco |
| Argenx US, INC. | $112.25 | 2024-2025 | Vyvgart Hytrulo |
| Takeda Pharmaceuticals U.S.A., INC. | $109.87 | 2024-2025 | Hyqvia |
| Lilly USA, LLC | $109.30 | 2024-2025 | Amyvid, Kisunla |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $109.18 | 2024-2025 | |
| Grifols USA, LLC | $77.03 | 2024-2025 | Gamunex-C |
| Amneal Pharmaceuticals LLC | $66.43 | 2024 | Rytary |
| Tanabe Pharma America, INC. | $65.55 | 2024 | |
| Pfizer INC. | $60.94 | 2024 | |
| Catalyst Pharmaceuticals, INC. | $56.25 | 2024 | |
| Averitas Pharma INC. | $55.17 | 2024-2025 | Qutenza |
| Emd Serono, INC. | $51.08 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $47.60 | 2025 | Wainua |
| Amgen INC. | $40.85 | 2024 | Uplizna |
| Philips North America LLC | $32.64 | 2024 | (5091) Amb Mon & Diag Und, (Ck4) Mcot |
| Janssen Pharmaceuticals, INC | $30.11 | 2024 | Spravato |
| Genentech USA, INC. | $27.63 | 2024 | Ocrevus |
| Impel Pharmaceuticals LLC | $24.95 | 2024 | Trudhesa |
| Inspire Medical Systems, INC. | $23.99 | 2025 | Inspire |
| Insightec,INC | $20.78 | 2025 | Exablate |
| Boston Scientific Corporation | $20.70 | 2025 | General - Dbs |
| Celgene Corporation | $18.27 | 2024 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Huott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.